These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30390909)

  • 1. Can Xolair Be Used in Nonallergic Asthmatic?
    Ledford DK; Casale TB
    J Allergy Clin Immunol Pract; 2018; 6(6):2170. PubMed ID: 30390909
    [No Abstract]   [Full Text] [Related]  

  • 2. Omalizumab treatment in asthma-COPD overlap syndrome.
    Tat TS; Cilli A
    J Asthma; 2016 Dec; 53(10):1048-50. PubMed ID: 27144514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO.
    Hanania NA; Chipps BE; Griffin NM; Yoo B; Iqbal A; Casale TB
    J Allergy Clin Immunol; 2019 Apr; 143(4):1629-1633.e2. PubMed ID: 30576755
    [No Abstract]   [Full Text] [Related]  

  • 4. [OMALIZUMAB RESCUED A ASTHMA-COPD OVERLAP SYNDROME PATIENT FROM A STATUS ASTHMATICS UNDER THE ICU MANAGEMENT].
    Gamo S; Iijima H; Seki Y; Horaguchi R; Suda Y; Shindoh Y
    Arerugi; 2016 Jul; 65(7):937-41. PubMed ID: 27545060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. World Asthma and COPD Forum. Clinical trial results with omalizumab.
    D'Amato G
    IDrugs; 2008 Jul; 11(7):489-92. PubMed ID: 18600594
    [No Abstract]   [Full Text] [Related]  

  • 6. Should omalizumab be used in severe asthma/COPD overlap?
    Sposato B; Scalese M; Milanese M; Masieri S; Cavaliere C; Ricci A; Paggiaro P
    J Biol Regul Homeost Agents; 2018; 32(4):755-761. PubMed ID: 30043557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different Skin Prick Test Sensitization Patterns Do Not Influence the Response to Omalizumab in Severe Asthma.
    Sposato B; Scalese M; Milanese M; Masieri S; Cavaliere C; Latorre M; Scichilone N; Matucci A; Vultaggio A; Ricci A; Cresti A; Paggiaro PL
    J Investig Allergol Clin Immunol; 2017; 27(6):388-391. PubMed ID: 29199967
    [No Abstract]   [Full Text] [Related]  

  • 8. Improvement of exertional dyspneoa in patients with chronic obstructive pulmonary disease and severe allergic asthma responding to omalizumab.
    Pereira S; Verhille J; Cailliau E; Bonniaud P; Devouassoux G; Fry S; Guilleminault L; Khayath N; Leroyer C; Chenivesse C; Bautin N
    Clin Exp Allergy; 2023 Dec; 53(12):1298-1301. PubMed ID: 37705326
    [No Abstract]   [Full Text] [Related]  

  • 9. Omalizumab discontinuation in children with severe allergic asthma: An observational real-life study.
    Deschildre A; Roussel J; Drumez E; Abou-Taam R; Rames C; Le Roux P; Pouessel G; Scalbert M; Bonnel C; Mitha S; Boileau S; Mordacq C; Thumerelle C; Labreuche J; Lejeune S; Marguet C
    Allergy; 2019 May; 74(5):999-1003. PubMed ID: 30481388
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study.
    Chen HC; Huang CD; Chang E; Kuo HP
    BMC Pulm Med; 2016 Jan; 16():3. PubMed ID: 26747278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab for Severe Asthma: Beyond Allergic Asthma.
    Loureiro CC; Amaral L; Ferreira JA; Lima R; Pardal C; Fernandes I; Semedo L; Arrobas A
    Biomed Res Int; 2018; 2018():3254094. PubMed ID: 30310816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Biological Agents in Asthma: Pharmacoeconomic Lessons Learned From Omalizumab.
    Draikiwicz S; Oppenheimer J
    Chest; 2017 Feb; 151(2):249-251. PubMed ID: 28183482
    [No Abstract]   [Full Text] [Related]  

  • 13. [Omalizumab, an anti-IgE monoclonal antibody to treat severe asthma].
    Michils A; Sternon J
    J Pharm Belg; 2006; 61(3):83-7. PubMed ID: 17058881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab could be effective in children with severe eosinophilic non-allergic asthma.
    Bourgoin-Heck M; Amat F; Trouvé C; Bernard A; Magny JP; Lambert N; Just J
    Pediatr Allergy Immunol; 2018 Feb; 29(1):90-93. PubMed ID: 28981968
    [No Abstract]   [Full Text] [Related]  

  • 15. Omalizumab: what do we learn from patients in treatment for more than ten years?
    Serpa FS; Chiabai J; Campinhos FL; Serpa AS; Braga Neto F
    J Bras Pneumol; 2020 Mar; 46(3):e20180352. PubMed ID: 32236342
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.
    Ledford D; Busse W; Trzaskoma B; Omachi TA; Rosén K; Chipps BE; Luskin AT; Solari PG
    J Allergy Clin Immunol; 2017 Jul; 140(1):162-169.e2. PubMed ID: 27826098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex differences in the efficacy, safety, and tolerability of omalizumab after 1 year in Maltese patients with asthma.
    Gouder C; Asciak R; Montefort S
    Ann Allergy Asthma Immunol; 2017 Apr; 118(4):513-514. PubMed ID: 28283278
    [No Abstract]   [Full Text] [Related]  

  • 18. [What can be done for problematic asthma patients?].
    Arnheim K
    MMW Fortschr Med; 2005 May; 147(21):4-6. PubMed ID: 15966163
    [No Abstract]   [Full Text] [Related]  

  • 19. Differential effect of omalizumab on pulmonary function in patients with allergic asthma with and without chronic rhinosinusitis.
    Clavenna MJ; Turner JH; Samuelson M; Tanner SB; Duncavage J; Chandra RK
    Allergy Asthma Proc; 2016; 37(1):23-6. PubMed ID: 26831843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omalizumab: a treatment for severe asthma in real life?
    Briquet A; Chanez P
    Rev Port Pneumol (2006); 2015; 21(3):111-2. PubMed ID: 25943448
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.